The Korea Food and Drug Administration (KFDA) is considering designating obesity treatments such as Wegovy (semaglutide) and Munjaro (tirzepatide) as drugs with a risk of misuse, prompting heightened attention from the medical and pharmaceutical industries.
According to industry sources, the KFDA announced on June 5 that it is reviewing a proposal to classify obesity treatments containing liraglutide, semaglutide, and tirzepatide as drugs with potential misuse risks due to concerns they may be used solely for weight loss rather than for their intended therapeutic purposes. The agency has been gathering feedback from industry stakeholders and related organizations until June 26 and is currently reviewing the input.
A KFDA official stated, "We will comprehensively review the opinions submitted last month and proceed with regulatory assessments before revising the guidelines. The timeline for completion is currently undecided."
If Wegovy and Munjaro are classified as drugs with misuse risks, the products will be required to display warning labels on their containers and packaging. Additionally, sales without a doctor's prescription will be prohibited even in areas exempt from the separation of prescribing and dispensing, thereby tightening regulations on distribution and sales. The authorities have expressed concerns about the rising issues of illegal online distribution and indiscriminate use for cosmetic purposes, highlighting the need for enhanced safety management.
In response, the medical community emphasizes that GLP-1 class treatments should be viewed as "chronic disease treatments" rather than merely weight loss drugs. They argue that obesity is closely linked to conditions like diabetes and cardiovascular diseases, and overly restrictive access to treatment could negatively impact patient management. They stress the importance of ensuring patient access to these critical medications, which play a vital role in managing diabetes and cardiovascular diseases.
The Korean Diabetes Association stated, "Simply designating GLP-1 receptor agonists as drugs with misuse risks is insufficient to effectively prevent misuse. A comprehensive monitoring system for prescriptions and distribution processes is necessary to block misuse." They further suggested that a specific and actionable management system should be established to reduce inappropriate prescriptions and illegal distribution while ensuring access for patients in need and providing accurate medical information to the public.
The pharmaceutical industry is also closely monitoring the policy direction. As the GLP-1 class treatments experience explosive growth in the global market, domestic companies are accelerating the development of related pipelines and technology adoption.
Domestic firms are pursuing the development of long-acting formulations and combination drugs, seeking differentiation as latecomers in the market. Analysts warn that increased regulation could slow market growth and impact investment and development strategies.
An industry insider remarked, "As the obesity treatment market rapidly expands, the label of 'drugs with misuse risks' could be a burden for the industry. We are closely watching market conditions."
However, some believe that a certain level of regulatory enhancement could actually increase market credibility. Establishing appropriate prescription systems and distribution management could reduce illegal distribution and exaggerated advertising, leading to improved perceptions of the treatments.
Jung Yoon-taek, director of the Pharmaceutical Industry Strategy Research Institute, stated, "It is necessary to limit indiscriminate prescriptions in consideration of public health, and since these are prescription medications, mechanisms for appropriate prescribing systems should be established."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.